[HTML][HTML] Relapse prediction model for immune-mediated thrombotic thrombocytopenic purpura
Background: Immune mediated thrombotic thrombocytopenic purpura (iTTP) is defined by
thrombocytopenia and microangiopathic hemolytic anemia caused by severely deficient …
thrombocytopenia and microangiopathic hemolytic anemia caused by severely deficient …
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
M Jestin, Y Benhamou, AS Schelpe… - Blood, The Journal …, 2018 - ashpublications.org
Preemptive rituximab infusions prevent relapses in immune thrombotic thrombocytopenic
purpura (iTTP) by maintaining normal ADAMTS13 activity. However, the long-term outcome …
purpura (iTTP) by maintaining normal ADAMTS13 activity. However, the long-term outcome …
Low levels of ADAMTS‐13 with high anti‐ADAMTS‐13 antibodies during remission of immune‐mediated thrombotic thrombocytopenic purpura highly predict for …
F Schieppati, L Russo, M Marchetti… - American Journal of …, 2020 - Wiley Online Library
Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a life‐threatening immune‐
mediated thrombotic microangiopathy. Daily therapeutic plasma exchange (TPE) and the …
mediated thrombotic microangiopathy. Daily therapeutic plasma exchange (TPE) and the …
[HTML][HTML] THE ROLE OF ADAMTS13 ACTIVITY LEVELS ON DISEASE EXACERBATION OR RELAPSE IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC …
JK HOVINGA, J DE LA RUBIA, K PAVENSKI… - … , Transfusion and Cell …, 2023 - Elsevier
Objective The management of exacerbations and disease relapse is important for patients
with immune-mediated thrombotic thrombocytopenic purpura (iTTP). Severe ADAMTS13 (a …
with immune-mediated thrombotic thrombocytopenic purpura (iTTP). Severe ADAMTS13 (a …
Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura
J Sui, W Cao, K Halkidis, MS Abdelgawwad… - Blood …, 2019 - ashpublications.org
Immune thrombotic thrombocytopenic purpura (iTTP) is primarily caused by immunoglobulin
G (IgG)–type autoantibodies that bind and inhibit plasma ADAMTS13 activity and/or …
G (IgG)–type autoantibodies that bind and inhibit plasma ADAMTS13 activity and/or …
Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura
K Pavenski, SHS Huang… - Expert Review of …, 2021 - Taylor & Francis
Introduction Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare
autoimmune blood disorder, which presents with microangiopathic hemolytic anemia …
autoimmune blood disorder, which presents with microangiopathic hemolytic anemia …
[HTML][HTML] Use of Preemptive Treatment for Immune Thrombotic Thrombocytopenic Purpura: A Matched Survival Analysis
Abstract Background: Immune Thrombotic thrombocytopenic purpura (iTTP) is a relapsing
disorder, resulting from depletion of ADAMTS13. With the goal of preventing clinical relapse …
disorder, resulting from depletion of ADAMTS13. With the goal of preventing clinical relapse …
Response Duration and Relapse Free Survival Shorten after Each Episode of Immune Thrombotic Thrombocytopenic Purpura (iTTP) Treated in the Rituximab Era
INTRODUCTION: Immune thrombotic thrombocytopenic purpura (iTTP) is caused by an
autoantibody mediated deficiency of ADAMTS13 and characterized by recurrent episodes of …
autoantibody mediated deficiency of ADAMTS13 and characterized by recurrent episodes of …
Assessment and monitoring of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP): strategies to improve outcomes
S Kucukyurt, AE Eskazan - Journal of Blood Medicine, 2020 - Taylor & Francis
Background Acquired or immune-mediated TTP (iTTP) is a life-threatening thrombotic
microangiopathy, characterized by the presence of microangiopathic hemolytic anemia and …
microangiopathy, characterized by the presence of microangiopathic hemolytic anemia and …
A Long-Term Follow-Up Study in Immune-Mediated Thrombotic Thrombocytopenic Purpura: What Are the Outcomes?
MA Bonifacio, D Roselli, CP Schifone, A Ricco… - Journal of Clinical …, 2023 - mdpi.com
Endothelium damage triggers the multimeric protein von Willebrand factor (VWF) release
and subsequent binding to platelets, which are recruited at sites of vascular injury. A …
and subsequent binding to platelets, which are recruited at sites of vascular injury. A …